Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine.

International journal of molecular sciences - 20 Mar 2026

Maharaj Dipnarine, Zhang Wen, Kaur Kawaljit, Gouvea Jacqueline

Abstract excerpt

Stem cells, also known as progenitor cells, can differentiate into specialized cells for specific tissues. Genetic mutations and epigenetic changes may cause normal stem cells to become cancer-initiating cells. Research indicates that cells acquiring a mutation for myeloproliferative neoplasm (MPN) are likely to be long-term hematopoietic stem cells (LT-HSCs) at the top of the hematopoietic hierarchy. Natural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Killer Cells, Natural

Share to Myeloproliferative Disorders

Share to Neoplastic Stem Cells

Share to Regenerative Medicine

Share to Tretinoin

Source

Open in PubMed Open full text

Identifiers

PMID: 41898674
DOI: 10.3390/ijms27062814
PMCID: PMC13027028

Genes

CALR
CD4
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interleukin-2 and Tretinoin for Myeloproliferative Neoplasms and to Target Type 1 Calreticulin-Driven Neoplasms: Advancements in Immune Regenerative Medicine.PMID 41898674Read ↗

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.Semantic proximity Read ↗

Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisSemantic proximity Read ↗

Myeloproliferative neoplasms: from origins to outcomes.Semantic proximity Read ↗

Myeloproliferative neoplasms: from origins to outcomes.Semantic proximity Read ↗

Effects of calreticulin mutations on cell transformation and immunity.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.Semantic proximity Read ↗

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Semantic proximity Read ↗

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.